Licensing In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer ups ante on Exubera approval with full license: Pfizer's decision to acquire Sanofi-Aventis' marketing rights to Exubera suggests the company is confident that the inhaled insulin product will receive FDA approval. Exubera's user fee date is Jan. 27, following a three-month extension resulting from an FDA request for additional technical chemistry data. Pfizer announced Jan. 12 that it will acquire worldwide rights for the development, production and commercialization of Exubera for $1.3 bil. - building on the firms' previous co-development alliance. The deal follows a judge's ruling that Sanofi's purchase of Aventis constituted a change-in-control under Pfizer and Aventis' 1998 agreement for Exubera. The NDA was submitted in March (1Pharmaceutical Approvals Monthly March 2005, p. 12)...
You may also be interested in...
Targanta’s Noninferiority Study Design Could Be Regulatory Hurdle For Oritavancin
Targanta may need to conduct additional clinical trials of its intravenous antibiotic oritavancin if FDA does not accept the company's use of a 15 percent noninferiority delta in its Phase III trial, according to the firm's initial public offering prospectus filed May 11 with the Securities & Exchange Commission.
AtheroGenics AGI-1067 Pivotal Data Expected In Late Q1
AtheroGenics’ atherosclerosis drug candidate AGI-1067 may qualify for multiple labeling claims in patient subpopulations including elderly patients, diabetics and women, CEO Russell Medford stated during the JP Morgan Healthcare Conference in San Francisco Jan. 10.
AtheroGenics AGI-1067 NDA On Track For H1’07; AstraZeneca Funding ARISE Extension
AtheroGenics is on track to submit an NDA for its atherosclerosis therapy AGI-1067 in the first half of 2007, the company said during a second-quarter investor call